SMPD1 and anterior segment dysgenesis: Enzyme replacement therapy (ERT) by intravenous infusion of recombinant human ASM efficiently treats the non‐neurological pathology in ASM‐KO mice (Miranda et al, 2000) and in ASMD patients (Wasserstein et al, 2015).